Hypericum Treatment of Mild Depressions with Somatic Symptoms

1994 ◽  
Vol 7 (1_suppl) ◽  
pp. 12-14 ◽  
Author(s):  
W.-D. Hübner ◽  
S. Lande ◽  
H. Podzuweit
Keyword(s):  
Treatment Group ◽  
Side Effects ◽  
Active Treatment ◽  
Somatic Symptoms ◽  
Active Treatment Group ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Disturbed Sleep ◽  
Hypericum Extract

In a randomized, placebo-controlled, double-blind study, 39 patients with depression with somatic symptoms were treated with hypericum extract LI 160. The therapy lasted for 4 weeks; the dosage was 300 mg three times daily. At the onset of the study as well as after 2 and 4 weeks, the following criteria were analyzed: HAMD, B-L, CGI, and vegetative symptoms. The results show a significant improvement in the active treatment group at the 5% level as compared to placebo. Seventy percent of the patients treated with LI 160 were free of symptoms after 4 weeks. Typical symptoms of the depression such as lack of activity, tiredness, fatigue, and disturbed sleep, were especially responsive. In no case were any undesirable side effects observed.

Multicenter Double-Blind Study Examining the Antidepressant Effectiveness of the Hypericum Extract LI 160

1994 ◽  
Vol 7 (1_suppl) ◽  
pp. 15-18 ◽  
Author(s):  
K.-D. Hänsgen ◽  
J. Vesper ◽  
M. Ploch
Keyword(s):  
Placebo Group ◽  
Side Effects ◽  
Statistical Evaluation ◽  
Blind Study ◽  
Double Blind Study ◽  
Psychometric Tests ◽  
Double Blind ◽  
Psychometric Scales ◽  
Hypericum Extract ◽  
Depressive Patients

Seventy-two depressive patients of 11 physicians’ practices were treated in a double-blind study for a period of 6 weeks either with hypericum extract LI 160 or with placebo. Inclusion criterion was a major depression in accordance with DSM-III-R. The changes were assessed using four psychometric scales (HAMD, D-S, BEB, CGI). After 4 weeks of therapy, the statistical evaluation revealed a significant improvement in all four psychometric tests in the active group as compared to the placebo group. After switching the placebo group to active treatment (5th to 6th week of therapy), significant improvements were found in the original placebo group. No serious side effects were observed.

A Clinical Trial of Hydroxyethylrutosides in the Treatment of Haemorrhoids of Pregnancy

1992 ◽  
Vol 20 (1) ◽  
pp. 54-60 ◽  
Author(s):  
H Wijayanegara ◽  
JC Mose ◽  
L Achmad ◽  
R Sobarna ◽  
W Permadi
Keyword(s):  
Clinical Trial ◽  
Treatment Group ◽  
Side Effects ◽  
Active Treatment ◽  
Controlled Trial ◽  
Active Treatment Group ◽  
Subjective Symptoms ◽  
Drug Related Problems ◽  
Double Blind ◽  
Safety And Efficacy

The safety and efficacy of 500 mg O-( β-hydroxyethyl)rutosides given orally twice daily in the treatment of 97 patients with first-, second-, or third-degree haemorrhoids were investigated in a double-blind, randomized placebo-controlled trial. The rutosides produced a significant ( P < 0.001) improvement in patient-assessed subjective symptoms (pain, bleeding, exudation and pruritus) compared with placebo. There was also a significant ( P < 0.0001) improvement in clinician-assessed subjective and objective signs (bleeding, inflammation and dilatation of the haemorrhoidal plexus) after 2 and 4 weeks' treatment compared with placebo. There were three mild, transient side-effects reported in the active treatment group and no drug-related problems in the pregnancy or delivery were observed. The results suggest that O-( β-hydroxyethyl)rutosides provide a safe and effective treatment for women with haemorrhoids of pregnancy.

The Efficacy and Tolerability of Combined Antidepressant Treatment in Different Depressive Subgroups

1993 ◽  
Vol 162 (3) ◽  
pp. 363-368 ◽  
Author(s):  
Sinead O'brien ◽  
Patrick McKeon ◽  
Myra O'regan
Keyword(s):  
Treatment Group ◽  
Side Effects ◽  
Major Depression ◽  
Orthostatic Hypotension ◽  
Antidepressant Treatment ◽  
Combined Treatment ◽  
Endogenous Depression ◽  
Double Blind Study ◽  
Double Blind ◽  
Global Improvement

Eighty patients admitted to hospital with major depression were randomly allocated to six weeks of treatment with tranylcypromine, amitriptyline, or tranylcypromine and amitriptyline in combination, in a double-blind study. Scores on the HRSD improved significantly in all three groups, but there were no differences between the three groups. Patients on tranylcypromine and amitriptyline combined improved more according to their self-ratings after six weeks, and response was earlier as measured by a clinical global improvement scale. Those with endogenous depression improved more than those with neurotic depression, irrespective of treatment group. Combined treatment was less well tolerated than single treatments and gave rise to more side-effects, although there was no serious toxicity. Orthostatic hypotension was observed more frequently in patients on combined treatment. This group also experienced a significant increase in weight and prolongation of the P-R interval on ECG.

scholarly journals A prospective randomised double blind study of the comparison of two opioids- fentanyl and buprenorphine – as adjuvant to spinal bupivacaine in caesarean sections

2017 ◽  
Vol 4 (1) ◽  
pp. 45
Author(s):  
Kamal Sonya ◽  
Davies C. V.
Keyword(s):  
Side Effects ◽  
Intrathecal Morphine ◽  
Maximum Level ◽  
Sensory Block ◽  
Local Anaesthetics ◽  
Blind Study ◽  
Maximum Height ◽  
Double Blind Study ◽  
Double Blind ◽  
Fentanyl Group

<p class="abstract"><strong>Background:</strong> Opioids are first introduced as additives to spinal anaesthesia in 1979, with intrathecal morphine as forerunner. Neuraxial opioids when added to local anaesthetics prolong the duration of sensory block, improve quality of block and no unwanted sympathetic blockade leading to hypotension. This prospective randomized double blind study was undertaken to evaluate the duration of analgesia, sensory and motor blocking properties and side effects of two opioids – Fentanyl and Buprenorphine, when used as adjuvant to spinal Bupivacaine in caesarean section.</p><p class="abstract"><strong>Methods:</strong> Sixty patients between the age group 18-35 years belonging to ASA I and II posted for elective LSCS were randomly divided into two groups. Each group consisting of 30 patients , received either 1.8 ml 0.5% Bupivacaine with 25 mcg Fentanyl (group F) or 1.8 ml 0.5% Bupivacaine with 75 mcg buprenorphine (Group B). The onset, maximum level and duration of sensory and motor blockade and hemodynamic parameters were monitored.</p><p class="abstract"><strong>Results:</strong> Maximum height of sensory block was achieved faster in fentanyl group (i.e. 4.09±1.12 minutes compared to 4.56±1.21 minutes in buprenorphine group). Duration of analgesia was significantly prolonged in buprenorphine group. It was 317±54 minutes and 214±35 minutes respectively for buprenorphine and fentanyl groups.</p><p class="abstract"><strong>Conclusions:</strong> The study thus concluded that although fentanyl produce faster sensory block, duration of analgesia is longer with buprenorphine, and both the drugs do not cause significant side effects.</p>

Zetidoline, A New Antipsychotic

1984 ◽  
Vol 145 (3) ◽  
pp. 294-299 ◽  
Author(s):  
T. Silverstone ◽  
S. Levine ◽  
H. L. Freeman ◽  
A. Dubini
Keyword(s):  
Side Effects ◽  
Dopamine Receptor ◽  
Blind Study ◽  
Double Blind Study ◽  
Extrapyramidal Side Effects ◽  
Double Blind ◽  
Receptor Blocking ◽  
Selective Dopamine

SummaryZetidoline (ZTD), a compound chemically unrelated to any available antipsychotic, with selective dopamine receptor-blocking properties, was compared with haloperidol (HLP) in a double-blind study on 56 in-patients who had either first episodes or acute relapses of schizophrenia. ZTD was found to be safe, as effective as HLP, and to produce significantly fewer extrapyramidal side-effects (EPS).

A Double-Blind Out-Patient Trial of Indalpine vs Mianserin

1985 ◽  
Vol 147 (3) ◽  
pp. 306-309 ◽  
Author(s):  
G. J. Naylor ◽  
B. Martin
Keyword(s):  
Side Effects ◽  
Treated Group ◽  
Blind Study ◽  
Antidepressant Effect ◽  
Double Blind Study ◽  
Double Blind ◽  
Significant Difference

SummaryIndalpine 150 mg per day and mianserin 60 mg per day were compared in a double-blind study of 65 depressed out-patients: 52 patients completed the 4-week trial. At the end of four weeks there was no significant difference in antidepressant effect between the two drugs; but in the first two weeks, improvement in the mianserin-treated group was significantly greater than that in the indalpine group. The mianserin-treated group reported more side-effects of sedation (eg. drowsiness, clumsiness, heaviness of limbs etc.) and one patient on indalpine developed a mild leucopenia.

Dronabinol or Ondansetron Alone and Combined for Delayed Chemotherapy-Induced Nausea and Vomiting (CINV).

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 5555-5555
Author(s):  
Haresh Jhangiani ◽  
James J. Vredenburgh ◽  
Lou Barbato ◽  
Haichen Yang ◽  
Hwa-Ming Yang ◽  
...  
Keyword(s):  
Treatment Group ◽  
Active Treatment ◽  
Statistical Significance ◽  
Active Treatment Group ◽  
Total Response ◽  
Standard Regimen ◽  
Double Blind ◽  
Treatment Groups ◽  
End Point ◽  
Group D

Abstract This randomized, double-blind, placebo-controlled, parallel-group study of the antiemetic efficacy and tolerability of oral dronabinol (D) alone, D in combination with ondansetron (O), O alone, or placebo (P) in patients receiving moderate to high emetogenic chemotherapy. All patients received dexamethasone 20 mg PO and O 16 mg IV prechemotherapy. Patients receiving D, O, or D+O also received D 2.5 mg before chemotherapy and after chemotherapy on Day 1 (combined active treatment group); group P did not receive D before or after chemotherapy. Day 2: P or fixed doses of 10 mg D, 16 mg O, or D+O were administered. Days 3–5: patients received P or flexible doses of 10–20 mg D, 8–16 mg O, or D+O. Primary efficacy variable was total response (TR=nausea intensity &lt;5 mm on a 100-mm visual analog scale, no vomiting/retching, no rescue antiemetic). Secondary efficacy parameters included nausea status and intensity and episodes of vomiting/retching. Active treatments were compared with each other and P on Days 2–5, and statistical significance was determined if P≤0.05 (unadjusted). Exploratory analyses were conducted post hoc to examine the effect of combined active treatment on Day 1 vs P. 64 patients were randomized and 61 analyzed for efficacy. On Day 1, in the combined active treatment group (n=50), significant improvement vs P (n=13) was observed for TR (79% vs 40%; P=0.024), mean nausea intensity (8 mm vs 31 mm; P=0.029), and absence of nausea (79% vs 38%; P=0.013), respectively. The end point efficacy results (Days 2–5 LOCF) for TR, nausea status/intensity, episodes of vomiting/retching are shown in the Table. On Days 2–5, TR was comparable for groups D and O. The percentage of patients without nausea was significantly greater in all treatment groups vs P. Nausea intensity was significantly reduced by all treatments vs P. The incidence of treatment-emergent AEs was similar among active treatment groups (71%–88%); AE rate in P-treated patients was 50%. Diarrhea and fatigue were the most common AEs (11%). Group D had a low incidence of CNS-related treatment-emergent AEs compared with Groups O and DO. The highest rates of the CNS-related events of dizziness and fatigue were observed in Group DO. Day 1 data suggest that the addition of dronabinol to the standard antiemetic regimen before and after chemotherapy may offer more benefit than the standard regimen alone. Thereafter, the antiemetic effect of D for delayed CINV was comparable with O. Results for D+O were similar to either agent alone. D was well tolerated. Efficacy Results at End Point Measure Units Group D, n=17 Group O, n=14 Group DO, n=17 Group P, n=13 *Cochran-Mantel-Haenszel. ‡Analysis of variance. †P≤ 0.05 vs P Median daily dose mg 20 16 17.5–20 D 12–16 O 0 Total response* % (frequency/n) 54 (7/13) 58† (7/12) 47 (7/15) 20 (2/10) Absence of nausea* % (frequency/n) 71† (10/14) 64† (9/14) 53† (9/17) 15 (2/13) Mean nausea intensity† mm (n) 10.1† (14) 24.0† (14) 14.3† (17) 48.4 (13) Mean vomiting/retching* episodes/day (n) 0.2 (13) 1.3 (12) 0.7 (17) 1.3 (10)

Comparative Efficacy of Lormetazepam (Noctamid®) and Diazepam (Valium®) in 100 Out-Patients with Insomnia

1981 ◽  
Vol 9 (3) ◽  
pp. 199-202 ◽  
Author(s):  
M Sastre y Hernández ◽  
H-D Hentschel ◽  
K Fichte
Keyword(s):  
Side Effects ◽  
Sleep Disorders ◽  
Blind Study ◽  
Double Blind Study ◽  
Comparative Efficacy ◽  
Double Blind ◽  
Better Than

Lormetazepam (Noctamid®) at a dosage of 1 mg was compared with diazepam (Valium®) at a dosage of 5 mg in a 7-day double-blind study. The study involved fifty patients in the lormetazepam group and fifty patients in the diazepam group. All the patients were suffering from sleep disorders as a concomitant symptom of general diseases. Lormetazepam was significantly better than diazepam in the: Reduction of the time taken to fall asleep (p < 0.05) Prolongation of the duration of uninterrupted sleep (p < 0.05) Reduction of the frequency of awakening (p < 0.05) Lormetazepam displayed no hang-over effects or other side-effects and, in this respect too, was significantly superior to diazepam (p < 0.05).

A Double Blind Study of the Effect of Tranexamic Acid in Essential Menorrhagia

1968 ◽  
Vol 20 (03/04) ◽  
pp. 583-587 ◽  
Author(s):  
J Vermylen ◽  
M. L Verhaegen-Declercq ◽  
M Verstraete ◽  
F Fierens
Keyword(s):  
Side Effects ◽  
Oral Administration ◽  
Tranexamic Acid ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind

SummaryOral administration of tranexamic acid, in a dosage of 3 g daily from the first day of menstruation onwards, significantly decreases menstrual haemoglobin loss in women with so-called essential menorrhagia.The frequency of side-effects reported did not differ between “active” and “placebo” periods.

Prevention of Rheumatic Fever

1973 ◽  
Vol 12 (8) ◽  
pp. 501-503 ◽  
Author(s):  
Ham Jackson
Keyword(s):  
Side Effects ◽  
Antibiotic Therapy ◽  
Rheumatic Fever ◽  
Streptococcal Pharyngitis ◽  
Blind Study ◽  
Effective Drug ◽  
Double Blind Study ◽  
Double Blind ◽  
Negative Results ◽  
Group A

Poststreptococcal sequelae can be markedly reduced by antibiotic therapy which eradicates the organism from the pharynx. In a double blind study, the effectiveness of clindamycin palmitate liquid was compared with that of ampicillin for eradicating group A beta hemolytic streptococci from patients with pharyngitis. Cultures four days posttherapy were negative in 95 (93.2%) of 102 clindamycin treated patients and in 92 (87.6%) of 105 in the ampicillin group. Seventy-six clindamycin treated and 79 ampicillin treated patients had 28-day cultures with negative results in 69 (90.8%) and 67 (84.8%), respectively. Possible side effects were both mild and infrequent, 3.8 per cent from ampicillin and 2.6 per cent from clindamycin. It was concluded that clindamycin palmitate is palatable, relatively free of side effects and is an effective drug for treatment of streptococcal pharyngitis. No poststreptococcal sequelae occurred.

Sign in / Sign up

Export Citation Format

Share Document